|
The Global Health Innovative Technology Fund (GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), seven Japanese pharmaceutical and diagnostics companies (Astellas, Chugai, Eisai, Daiichi Sankyo, Shionogi, Sysmex and Takeda), the Bill & Melinda Gates Foundation, the Wellcome Trust and United Nations Development Programme. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world.〔“Japan in pioneering partnership to fund global health research”, by Andrew Jack, ''Financial Times'', May 30, 2013〕〔“Japanese Global Health Fund Welcomes the Wellcome Trust and Sysmex Corporation as New Funders and ANA, Morrison & Foerster, and Yahoo! Japan as New Sponsors”, PR Newswire, June 3, 2015, (http://www.prnewswire.com/news-releases/japanese-global-health-fund-welcomes-the-wellcome-trust-and-sysmex-corporation-as-new-funders-and-ana-morrison--foerster-and-yahoo-japan-as-new-sponsors-300093066.html), accessed on 9/28/2015〕 == Role in Global Health Sector == The GHIT Fund is the first public-private partnership fund to involve a national government, a UN agency, a consortium of pharmaceutical and diagnostics companies, and international philanthropic foundations.〔“The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations”, by BT Slingsby and Kiyoshi Kurokawa, The Lancet: Global Health, October 2013, Volume 1, pp.e184-185 (http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70055-X/fulltext)〕〔“Investing In Drugs That Won't Make Money”, Forbes, April 30, 2015, (http://www.forbes.com/sites/medidata/2015/04/30/investing-in-drugs-that-wont-make-money/), accessed on 9/28/2015〕 It was founded in 2013 with an initial commitment of over US$100 million after the government of Japan made global health a key priority within its overseas development aid budget.〔“The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations”, by BT Slingsby and Kiyoshi Kurokawa, ''The Lancet'': Global Health, October 2013, Volume 1, pp.e184-185 (http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70055-X/fulltext)〕 The Fund is built on the idea that new investment and innovation is needed to address some of the world’s most neglected diseases〔“Japan and Partners Team Up to Tackle Neglected Diseases”, by Dina Fine Maron, ''Scientific American'', November 8, 2013 (http://www.scientificamerican.com/article.cfm?id=japan-and-partners-team)〕 and that Japan – a leader in health technologies innovation – could be doing more in the global fight against infectious diseases.〔“Joining the Fight Against Neglected Diseases”, ''Science'' magazine, June 7, 2013, Volume 340, p.1148〕 The public-private partnership model, the inclusion of a while pharmaceutical sector and the structure of individual research projects across sectors and national boundaries are all aimed at reducing the R&D risk to any one entity and to ensure that findings are open to all, according to the Fund's CEO and Executive Director BT Slingsby.〔“Investing In Drugs That Won't Make Money”, Forbes, April 30, 2015, (http://www.forbes.com/sites/medidata/2015/04/30/investing-in-drugs-that-wont-make-money/), accessed on 9/28/2015〕 Because of the business model of the Fund and the structure of the partnerships it funds, some view the Fund as a game-changer for global health financing. For instance, Dr. Margaret Chan, Director-General of the World Health Organization, said: "The GHIT Fund has stepped in to provide that incentive in a pioneering model of partnership that brings Japanese innovation, investment and leadership to the global fight against infectious disease."〔See WHO's video featuring Margeret Chan, WHO Director-General, here: https://ghitfund.org/general/eventreport2015〕 One specific asset the Japan pharmaceutical industry contributes is access to its vast library of chemical compounds coming out of prior drug research; the Fund's partner companies have agreed to open up these compound libraries to research with the Drugs for Neglected Disease Initiative, joining UK-based AstraZeneca in the effort.〔“Japanese Companies Attack Neglected Diseases”, by Donald G. McNeill Jr., New York Times, June 1, 2015, (http://www.nytimes.com/2015/06/02/health/japanese-companies-attack-neglected-diseases.html?_r=0) , accessed on 09/18/2015〕 "Another key opportunity the GHIT Fund has created has been to help open the doors of Japan’s public and private drug compound libraries to product development partnerships, which makes possible the screening of tens of thousands of drug candidates for potential new treatments."〔“The Value of Product Development Partnerships”, The National Bureau of Asian Research, August 11, 2014 (http://nbr.org/research/activity.aspx?id=477)〕 The participating companies view their investments into neglected diseases through the Fund as a long-term investment into the future, rather than charity. They see the Fund as a necessary catalyst for having allowed them to pursue this line of research.〔“Japanese drugmakers addressing neglected tropical diseases, and not just out of altruism”, Japan Times, January 6, 2015, (http://www.japantimes.co.jp/news/2015/01/06/national/science-health/japanese-drugmakers-addressing-neglected-tropical-diseases-and-not-just-out-of-altruism?utm_campaign=KFF%3A+Global+Health+Report&utm_source=hs_email&utm_medium=email&utm_content=15472323&_hsenc=p2ANqtz--eDo7Aql3yZTIYzqLd8ch1nlYuggQTgOmjz3-32M9gn3IulHDQnVAXK4sEdynfIurWMlME9f6XH2GM2yYZ01Wl9LtgANF7bQ7IlKTqV50R7P0ngro&_hsmi=15472323#.Vgm81SvSta-), accessed on 9/28/2015〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Global Health Innovative Technology Fund (GHIT)」の詳細全文を読む スポンサード リンク
|